Abstract
Background: We have previously demonstrated that adrenaline (AD) is released into the circulation during acute myocardial infarction and is associated with a more severe clinical course. The role of elevated AD levels in congestive heart failure is not known.
Hypothesis: The study aimed to determine whether increased daily AD excretion is associated with more severe clinical symptoms and a more complicated clinical course in patients with exacerbation of congestive heart failure (CHF).
Methods: Urinary excretion of AD, noradrenaline, magnesium (Mg), and potassium (K), serum levels of aldosterone, K, and Mg, as well as the incidence of arrhythmias (24‐h Holter) were assessed in 49 patients with CHF New York Heart Association (NYHA) class II‐III. The patients were allocated to two groups, with normal (Group 1) and increased (Group 2) excretion of AD.
Results: Groups 1 and 2 did not differ in respect of age, etiology of CHF, or the medication used. Also, left ventricular ejection fraction was similar in the two groups. However, left ventricular end‐diastolic dimension was greater in Group 2 (61 ± 9 vs. 55 ± 11 mm, p < 0.05), as was the proportion of patients in NYHA class III (74 vs. 40%). Group 2 was also characterized by increased urinary excretion of Mg (60 ± 24 vs. 43 ± 16 mg/24 h, p < 0.007) and the presence of more complex and numerous ventricular arrhythmias (74 vs. 37% and 68 vs. 33% of patients, respectively).
Conclusions: Urinary excretion of AD is increased only in a subgroup of patients with CHF. These patients are characterized by a more advanced NYHA class, increased end‐diastolic left ventricular diameter, and increased urinary excretion of magnesium. It is likely that all these factors contribute to the presence of more complex and numerous ventricular arrhythmias in this subgroup of patients.
Keywords: heart failure, adrenaline, noradrenaline, clinical features
Full Text
The Full Text of this article is available as a PDF (526.7 KB).
References
- 1. Massie BM, Packer M: Congestive heart failure: Current controversies and future prospects. Am J Cardiol 1990: 66: 429–430 [Google Scholar]
- 2. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis G, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–823 [DOI] [PubMed] [Google Scholar]
- 3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730–1736 [DOI] [PubMed] [Google Scholar]
- 4. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD: Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993; 88: 136–145 [DOI] [PubMed] [Google Scholar]
- 5. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD: Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26: 1257–1263 [DOI] [PubMed] [Google Scholar]
- 6. Goldstein DS: Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. Am J Cardiol 1981; 48: 1147–1154 [DOI] [PubMed] [Google Scholar]
- 7. Esler M, Kaye D, Lambert G, Esler D, Jennings G: Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80 (suppl 11A): 7L–14L [DOI] [PubMed] [Google Scholar]
- 8. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R, for the V‐HeFT VA Cooperative Studies Group : Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87 (suppl VI): VI‐5–VI‐16 [PubMed] [Google Scholar]
- 9. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD: Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23: 570–578 [DOI] [PubMed] [Google Scholar]
- 10. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin U, Goldstein DS, Esler MD: Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1667–1676 [DOI] [PubMed] [Google Scholar]
- 11. Kaye DM, Lefkovits J, Cox H, Lambert G, Jennings G, Turner A, Esler MD: Regional epinephrine kinetics in human heart failure: Evidence for extra‐adrenal, nonneural release. Am J Physiol 1995; 269:H182–H188 [DOI] [PubMed] [Google Scholar]
- 12. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN: Activity of the sympathetic nervous system and renin‐angiotensin system by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 1659–1666 [DOI] [PubMed] [Google Scholar]
- 13. Anker SD: Catecholamine levels and treatment in chronic heart failure. Eur Heart J 1998; 19 (suppl F): F56–F61 [PubMed] [Google Scholar]
- 14. Staszewska‐Barczak J, Ceremuzynski L: The continuous estimation of catecholamine release in the early stages of myocardial infarction in the dog. Clin Sci 1968; 34: 531–539 [PubMed] [Google Scholar]
- 15. Ceremuzynski L, Staszewska‐Barczak J, Herbaczynska‐Cedro K: Cardiac rhythm disturbances and the release of catecholamines after acute coronary occlusion in dogs. Cardiovasc Res 1969; 3: 190–197 [DOI] [PubMed] [Google Scholar]
- 16. Markiewicz L, Ceremuzynski L, Kuch J: Blood and urine catecholamines in recent myocardial infarction, after attack of angina pectoris, and in non‐cardiac pain (pleuritis). Cor Vasa 1973; 15: 9–19 [PubMed] [Google Scholar]
- 17. Ceremuzynski L, Herbaczynska‐Cedro K, Ruthven CRJ, Goodwin BL, Weg MW, Lax PM, Sandler M: Augmented excretion of catecholamine metabolites in myocardial infarction of mild course and increased excretion of free catecholamines in the complicated disease In Myocardial Ischemia and Protection, p. 101–108 (Eds. Refsum H, Jynge P, Mjøs OD.). Edinburgh: Churchill Livingstone Co., 1983. [Google Scholar]
- 18. Holmes J, Kubo SH, Cody RJ, Kligfield P: Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: Prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985; 55: 146–151 [DOI] [PubMed] [Google Scholar]
- 19. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, Goldstein S: Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril‐Digoxin Study Group. J Am Coll Cardiol 1989; 14: 564–570 [DOI] [PubMed] [Google Scholar]
- 20. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O, Perrone SV, for the GESICA‐GEMA Investigators : Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. Circulation 1996; 94: 3198–3203 [DOI] [PubMed] [Google Scholar]
- 21. Maggioni AP, Zuanetti G, Franzosi MG, Rovelli F, Santoro E, Stasewsky L, Tavazzi L, Tognoni G, and GISSI‐2 Investigators : Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI‐2 results. Circulation 1993; 86: 312–322 [DOI] [PubMed] [Google Scholar]
- 22. Esler M, Eisenhofer G, Chin J, Jennings G, Meredith I, Cox H, Lambert G, Thompson J, Dart A: Is adrenaline released by sympathetic nerves in man? Clin Auton Res 1991; 1: 103–108 [DOI] [PubMed] [Google Scholar]
- 23. Van Veldhuisen DJ, Crijns HJ, Girbes AR, Tobe TJ, Wiesfeld AC, Lie KI: Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. Am J Cardiol 1991; 68: 1194–1202 [DOI] [PubMed] [Google Scholar]
- 24. Kurose M, Okumura K, Ogawa H, Yoshimura M, Morita E, Yasue H: Reduced cardiac extraction of norepinephrine and epinephrine in patients with heart failure: Correlation with left ventricular function. Int J Cardiol 1994; 47: 21–29 [DOI] [PubMed] [Google Scholar]
- 25. Johansson M, Rundqvist B, Eisenhofer G, Friberg P: Cardiorenal epinephrine kinetics: Evidence for neuronal release in the human heart. Am J Physiol 1997; 273: H2178–H2185 [DOI] [PubMed] [Google Scholar]
- 26. Francis GS, Goldsmith SR, Ziesche SM, Cohn JN: Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol 1982; 49: 1152–1156 [DOI] [PubMed] [Google Scholar]
- 27. Francis GS, Goldsmith SR, Pierpont G, Cohn JN: Free and conjugated plasma catecholamines in patients with congestive heart failure. J Lab Clin Med 1984; 103: 393–398 [PubMed] [Google Scholar]
- 28. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K: Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984; 54: 783–786 [DOI] [PubMed] [Google Scholar]
- 29. Viquerat CE, Daly P, Swedberg K, Evers C, Curran D, Parmley WW, Chatterjee K: Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med 1985; 78: 455–460 [DOI] [PubMed] [Google Scholar]
- 30. Schwarz PJ, Priori SG: Sympathetic nervous system and cardiac arrhythmias In Cardiac Electrophysiology. From Cell to Bedside, p. 330–343 (Eds. Zipes DP, Jalife J.). Philadelphia: WB Saunders Co., 1990. [Google Scholar]
- 31. Reiter MJ: Effects of mechano‐electrical feedback: Potential arrhythmogenic influence in patients with congestive heart failure. Cardiovasc Res 1996; 32: 44–51 [PubMed] [Google Scholar]
- 32. Ceremuzynski L, Gebalska J, Wolk R, Makowska E: Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Int Med 2000: 247: 78–86 [DOI] [PubMed] [Google Scholar]